{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:44:25Z","timestamp":1773240265011,"version":"3.50.1"},"reference-count":51,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2007,8,29]],"date-time":"2007-08-29T00:00:00Z","timestamp":1188345600000},"content-version":"vor","delay-in-days":28,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2007,8]]},"abstract":"<jats:p>\n                    <jats:bold>\n                      <jats:sc>Abstract<\/jats:sc>\n                      :\u2002\n                    <\/jats:bold>\n                    <jats:bold>This article will focus on the relationship between serum levels of anti\u2010citrullinated peptide antibodies (anti\u2010CCP) or rheumatoid factor (RF) and clinical response to TNF\u2010\u03b1 blockers in order to evaluate whether these antibodies may have a role as serological markers of response to therapy in rheumatoid arthritis (RA). The changes induced in anti\u2010CCP levels after TNF blocking therapy still remain a controversial issue even though a marked reduction following conventional DMARDs has been reported in early disease. On the other hand, a drop in RF levels during treatment has been reported by many authors. Decreased IgM RF levels seem to parallel clinical response suggesting that this antibody can also be regarded as a marker of response to treatment. Pre\u2010treatment RF positivity or negativity does not influence response to TNF\u2010\u03b1 blocking therapy while high pre\u2010treatment levels of IgA RF seem to be associated with a poor response rate.<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1196\/annals.1398.034","type":"journal-article","created":{"date-parts":[[2007,9,4]],"date-time":"2007-09-04T01:08:39Z","timestamp":1188868119000},"page":"287-295","source":"Crossref","is-referenced-by-count":36,"title":["Predictive Value of Antibodies to Citrullinated Peptides and Rheumatoid Factors in Anti\u2010TNF\u2010\u03b1 Treated Patients"],"prefix":"10.1111","volume":"1109","author":[{"given":"FRANCESCA","family":"BOBBIO\u2010PALLAVICINI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ROBERTO","family":"CAPORALI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CLAUDIA","family":"ALPINI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"REMIGIO","family":"MORATTI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CARLOMAURIZIO","family":"MONTECUCCO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,29]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"468","article-title":"Anti\u2010citrullinated protein\/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor","volume":"4","author":"Vander Cruyssen B.","year":"2005","journal-title":"Rev."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.014233"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016808"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033571"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.5.427"},{"key":"e_1_2_6_8_2","first-page":"231","article-title":"Predictive value of antibodies to cyclic citrullinated peptide in patients with very early inflammatory arthritis","volume":"32","author":"Raza K.","year":"2005","journal-title":"J. Rheumatol."},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(76)90094-5"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.6.505"},{"key":"e_1_2_6_11_2","first-page":"1037","article-title":"Routine measurement of IgM, IgG, and IgA rheumatoid factors: high sensitivity, specificity, and predictive value for rheumatoid arthritis","volume":"24","author":"Swedler W.","year":"1997","journal-title":"J. Rheumatol."},{"key":"e_1_2_6_12_2","first-page":"113","article-title":"Rheumatoid factor isotypes and circulating immune complexes in rheumatoid arthritis","volume":"8","author":"Zlabinger G.J.","year":"1990","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_2_6_13_2","first-page":"301","article-title":"IgA isotype rheumatoid factor in rheumatoid arthritis: clinical implications","volume":"14","author":"Jorgensen C.","year":"1996","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.041376"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01993268"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330816"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310902"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.45.3.183"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780290404"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0162-3109(95)00041-0"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.54.4.256"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02206834"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02231579"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.20659"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780260503"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1173"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.023523"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1851"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.014647"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030262"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-004-0571-9"},{"key":"e_1_2_6_33_2","first-page":"756","article-title":"Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab","volume":"22","author":"Allanore Y.","year":"2004","journal-title":"Clin. Exp. Rheumatol."},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.038851"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.008599"},{"key":"e_1_2_6_36_2","first-page":"134","article-title":"Correlation between different clinical activity and anti\u2010CCP (anti\u2010cyclic citrullinated peptide antibodies) titres in rheumatoid arthritis treated with three different tumour necrosis factors TNF\u2010\u03b1 blockers","volume":"97","author":"Benucci M.","year":"2006","journal-title":"Recenti Prog. Med."},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.060608"},{"key":"e_1_2_6_38_2","first-page":"275\u2010 282","article-title":"TNF\u03b1 inhibition in anti\u2010Ro\/SSa positive patients with rheumatoid arthritis: clinical and immunological effects","volume":"58","author":"Cavazzana I.","year":"2006","journal-title":"Reumatismo"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.024182"},{"key":"e_1_2_6_40_2","first-page":"2557","article-title":"Induction of autoantibodies during prolonged treatment with Infliximab","volume":"30","author":"Louis M.","year":"2003","journal-title":"J. Rheum."},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.018093"},{"key":"e_1_2_6_42_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.10697","article-title":"Adalimumab, a fully human anti\u2010tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial","volume":"48","author":"Weinblatt M.E.","journal-title":"Arthritis Rheum."},{"key":"e_1_2_6_43_2","first-page":"S141","article-title":"Unusual toxicities with TNF inhibition: heart failure and drug\u2010induced lupus","volume":"22","author":"Cush J.J.","year":"2004","journal-title":"Clin. Exp. rheumatol"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar1440"},{"key":"e_1_2_6_45_2","first-page":"348","article-title":"Anticorpi antinucleo e trattamento con 3 differenti agenti anti\u2010tumour necrosis factor\u2010\u03b1[abstract]","volume":"58","author":"Atzeni F.","year":"2006","journal-title":"Reumatismo"},{"key":"e_1_2_6_46_2","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/ard.2004.024737","article-title":"Anti\u2010TNF(alpha) therapy in rheumatoid arthritis: an update on safety","volume":"63","author":"Hyrich K.L.","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390105"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032534"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21650"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel149"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21778"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10092"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1196%2Fannals.1398.034","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1196\/annals.1398.034","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T06:52:20Z","timestamp":1695624740000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1398.034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["10.1196\/annals.1398.034"],"URL":"https:\/\/doi.org\/10.1196\/annals.1398.034","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1105073.561247","asserted-by":"object"}]},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}